EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Vagus nerve stimulation therapy for treatment-resistant PTSD

Mark B Powers, Seth A Hays, David Rosenfield, Amy L Porter, Holle Gallaway, Greg Chauvette, Jasper A J Smits, Anne Marie Warren, Megan Douglas, Richard Naftalis, Jane G Wigginton, M Foreman und 2 weitere

Brain Stimulation · 2025-05 · 18 (3) · 665-675

DOI: 10.1016/j.brs.2025.03.007 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Brain Stimulation, 2025-05. Verfasst von Mark B Powers und 13 weiteren Autor:innen. Beteiligte Einrichtung: Baylor Scott & White Research Institute, Dallas, TX 75246, USA. Electronic address: mark.powers1@bswhealth.org. Hauptthemen laut MEDLINE: Stress Disorders, Post-Traumatic, Vagus Nerve Stimulation. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Defense Advanced Research Projects Agency, Defense Advanced Research Projects Agency Biological Technologies Office.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Posttraumatic stress disorder (PTSD) is common and debilitating, and many individuals do not respond to existing therapies. We developed a fundamentally novel neuromodulation-based therapy for treatment-resistant PTSD. This approach is premised on coupling prolonged exposure therapy, a first-line evidence-based cognitive behavioral therapy that directs changes within fear networks, with concurrent delivery of short bursts of vagus nerve stimulation (VNS), which enhance synaptic plasticity. METHODS: We performed a first-in-human prospective open-label early feasibility study (EFS) using a next-generation miniaturized system to deliver VNS therapy in nine individuals with moderate to severe treatment-resistant PTSD. All individuals received a standard 12-session course of prolonged exposure therapy combined with VNS. Assessments were performed before, 1 week after, and 1, 3, and 6 months after the completion of therapy. CLINICALTRIALS: gov registration: NCT04064762. RESULTS: VNS therapy resulted in significant, clinically-meaningful improvements in multiple metrics of PTSD symptoms and severity compared to baseline (CAPS-5, PCL-5, and HADS all p < 0.001 after therapy). These benefits persisted at 6 months after the cessation of therapy, suggesting lasting improvements. All participants showed loss of PTSD diagnosis after completing treatment. No serious or unexpected device-related adverse events were observed. CONCLUSIONS: These findings provide a demonstration of the safety and feasibility of VNS therapy for PTSD and highlight the potential of this approach. Collectively, these support the validation of VNS therapy for PTSD in a rigorous randomized controlled trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stress Disorders, Post-TraumaticVagus Nerve StimulationHumansMaleFemaleMiddle AgedAdultTreatment OutcomeFeasibility StudiesProspective Studies

Stichwörter der Autor:innen

Cognitive behavioral therapyPosttraumatic stress disorderProlonged exposure therapyVagal nerve stimulationVagus nerve stimulation

Autor:innen und Institutionen

  • Baylor Scott & White Research Institute, Dallas, TX 75246, USA. Electronic address: mark.powers1@bswhealth.org.
  • Department of Bioengineering, Erik Jonsson School of Engineering and Computer Science, University of Texas at Dallas, Richardson, TX 75080, USA; Texas Biomedical Device Center, University of Texas at Dallas, Richardson,…
  • Department of Psychology, Southern Methodist University, Dallas, TX 75275, USA.
  • Texas Biomedical Device Center, University of Texas at Dallas, Richardson, TX 75080, USA.
  • Baylor Scott & White Research Institute, Dallas, TX 75246, USA.
  • Department of Psychology and Institute for Mental Health Research, The University of Texas at Austin, Austin, TX 78712, USA.

Förderung

  • Defense Advanced Research Projects Agency
  • Defense Advanced Research Projects Agency Biological Technologies Office

Zitieren

APA

Powers, M. B., Hays, S. A., Rosenfield, D., Porter, A. L., Gallaway, H., Chauvette, G., Smits, J. A. J., Warren, A. M., Douglas, M., Naftalis, R., Wigginton, J. G., Foreman, M., Kilgard, M. P., & Rennaker, R. L. (2025). Vagus nerve stimulation therapy for treatment-resistant PTSD. Brain Stimulation, 18(3), 665-675. https://doi.org/10.1016/j.brs.2025.03.007

Vancouver

Powers MB, Hays SA, Rosenfield D, Porter AL, Gallaway H, Chauvette G, et al. Vagus nerve stimulation therapy for treatment-resistant PTSD. Brain Stimulation. 2025;18(3):665-675. doi:10.1016/j.brs.2025.03.007

BibTeX
@article{Powers2025,
  author = {Powers, Mark B and Hays, Seth A and Rosenfield, David and Porter, Amy L and Gallaway, Holle and Chauvette, Greg and Smits, Jasper A J and Warren, Anne Marie and Douglas, Megan and Naftalis, Richard and Wigginton, Jane G and Foreman, M and Kilgard, Michael P and Rennaker, Robert L},
  title = {Vagus nerve stimulation therapy for treatment-resistant PTSD},
  journal = {Brain Stimulation},
  year = {2025},
  volume = {18},
  number = {3},
  pages = {665--675},
  doi = {10.1016/j.brs.2025.03.007}
}
Kostenlos starten →